周四盘前，疫苗制造商诺瓦瓦克斯医药（NVAX）股价大幅下跌5.03%，引发市场关注。
此次股价下跌主要源于美国银行的最新分析报告。美银分析师将诺瓦瓦克斯医药的投资评级从"中性"下调至"跑输大市"，同时将目标价从9美元下调至7美元。这一举动反映了分析师对该公司未来表现的担忧，可能会影响投资者信心。
作为一家专注于开发和商业化新型疫苗的生物技术公司，诺瓦瓦克斯医药在新冠疫情期间备受关注。然而，随着疫情影响逐渐减弱，市场对疫苗需求的预期也随之下降。美银此次下调评级可能意味着分析师对公司在后疫情时代的业务前景持谨慎态度。投资者将密切关注诺瓦瓦克斯医药的后续表现，以及公司如何应对当前的市场挑战。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.